BI 1815368
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim
Conditions
Centre-involved diabetic macular edemaHealthyMacular Edema
Phase 1
A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men
CompletedNCT05857878
Start: 2023-06-23End: 2024-06-06Updated: 2024-11-19
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood
CompletedNCT05965583
Start: 2023-08-02End: 2023-10-24Updated: 2026-05-12
A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men
CompletedNCT06494774
Start: 2024-08-19End: 2024-11-13Updated: 2025-01-22
A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body
CompletedNCT06655220
Start: 2024-11-08End: 2025-01-13Updated: 2025-03-05
Phase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RecruitingNCT06962839
Start: 2025-06-05End: 2027-09-29Target: 300Updated: 2026-09-03
A randomised, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with centre-involved diabetic macular edema for 48 weeks of treatment (THULITE)
RecruitingCTIS2024-520384-14-00
Start: 2025-11-20Target: 193Updated: 2025-10-06